Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:AGRX

Agile Therapeutics (AGRX) Stock Price, News & Analysis

Agile Therapeutics logo

About Agile Therapeutics Stock (NASDAQ:AGRX)

Key Stats

Today's Range
$1.51
$1.52
50-Day Range
$1.43
$1.51
52-Week Range
$0.20
$2.63
Volume
120,900 shs
Average Volume
352,864 shs
Market Capitalization
$10.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Agile Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
3rd Percentile Overall Score

AGRX MarketRank™: 

Agile Therapeutics scored higher than 3% of companies evaluated by MarketBeat, and ranked 960th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Agile Therapeutics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Agile Therapeutics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for AGRX.
  • Dividend Yield

    Agile Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Agile Therapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for AGRX.
  • MarketBeat Follows

    1 people have added Agile Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Agile Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.50% of the stock of Agile Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 10.92% of the stock of Agile Therapeutics is held by institutions.

  • Read more about Agile Therapeutics' insider trading history.
Receive AGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGRX Stock News Headlines

Blackrock’s Sending THIS Crypto Higher on Purpose
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
See More Headlines

AGRX Stock Analysis - Frequently Asked Questions

Agile Therapeutics, Inc. (NASDAQ:AGRX) released its earnings results on Tuesday, November, 2nd. The specialty pharmaceutical company reported ($7.20) earnings per share for the quarter, topping the consensus estimate of ($7.60) by $0.40. The specialty pharmaceutical company had revenue of $1.29 million for the quarter, compared to analysts' expectations of $1.49 million.

Agile Therapeutics shares reverse split on the morning of Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Agile Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), CrowdStrike (CRWD) and Arista Networks (ANET).

Company Calendar

Last Earnings
11/02/2021
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AGRX
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Net Income
$-14,470,000.00
Pretax Margin
-36.24%

Debt

Sales & Book Value

Annual Sales
$19.98 million
Book Value
($5.51) per share

Miscellaneous

Free Float
6,822,000
Market Cap
$10.35 million
Optionable
Not Optionable
Beta
1.58

Social Links

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (NASDAQ:AGRX) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners